{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006837","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.256267+00:00","generated_at":"2026-05-16T02:24:22.894958+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs","bullets":["Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.","Gross proceeds ~$5.0M net of ~7% placement agent fee and expenses.","Proceeds to fund BRTX-100 Phase 2 trial, ThermoStem R&D, biocosmeceuticals platform, and working capital.","Rodman & Renshaw acted as exclusive placement agent; 90-day lockup on new equity issuances."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006837","json":"https://secwatch.observer/filing/0001493152-26-006837.json","markdown":"https://secwatch.observer/filing/0001493152-26-006837.md","text":"https://secwatch.observer/filing/0001493152-26-006837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000149315226006837/0001493152-26-006837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000149315226006837/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:24:22.894958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"495cf71e7bcecb25512fc961e6a4039fbb774a68","claim":"BioRestorative Therapies, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2026-02-11).","evidence_excerpt":"On February 11, 2026, BioRestorative Therapies, Inc. (the “Company”) commenced a public offering (the “Offering”) of an aggregate of (a) 12,560,715 units (the “Common Units”), consisting of (i) 12,560,715 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) five-year warrants to purchase up to 12,560,715 shares of Common Stock (the “Common Stock Warrants”), at an offering price of $0.35 per Common Unit, and (b) 1,725,000 units (the “Pre-Funded Units”), consisting of (i) pre-funded warrants to purchase up to 1,725,000 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) five-year warrants to purchase up to 1,725,000 shares of Common Stock, at an offering price of $0.3499 per Pre-Funded Unit.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000149315226006837/0001493152-26-006837-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2026-02-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}